IRTC | Ticker Profile - Titan Protect

IRTC

iRhythm Holdings, Inc.

Healthcare · Medical Devices · NMS

$108.11

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

106.77

Based on estimated future earnings — lower means cheaper

Rev Growth

+25.7%

Year-over-year revenue change

Profit Margin

-3.5%

How much profit the company keeps from each dollar of revenue

ROE

-22.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$180.00

+67% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 14 analysts covering this stock

About iRhythm Holdings, Inc.

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

https://www.irhythmtech.com

Country: United States Employees: 2,400 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.533

Good returns relative to risk taken

Kelly Fraction

0.0459

Modest edge detected — smaller position warranted

Calmar Ratio

0.331

Drawdown risk outweighs the returns — higher risk profile

Annual Return

15.5%

Historical annualised return based on price data

Max Drawdown

-47.0%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

205

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.33

Moves slightly more than the broader market

52W High

$212.00

49% below the year high

52W Low

$108.81

-1% above the year low

Avg Volume

548,885

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

9.5%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.85

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

452.39

Heavy leverage — higher financial risk if revenues decline

Current Ratio

5.17

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

4.79

Like current ratio but excludes inventory — stricter test

Gross Margin

71.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-5.9%

Profit from core operations before interest and tax

Free Cash Flow

$57M

Positive — the business generates more cash than it spends

Revenue (TTM)

$788M

Total revenue over the last 12 months

Net Income

$-27,784,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$255.00

Target Median

$180.00

Target Low

$147.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go